Kinnate Biopharma (KNTE) Stock Price, News & Analysis

Company Overview

Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

Key Stats

• Today's Range: $2.65 to $2.65
• 50-Day Range: $2.45 to $2.66
• 52-Week Range: $1.04 to $7.18
• Volume: N/A
• Average Volume: 418,678 shs
• Market Capitalization: $125.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

KNTE Stock Analysis - Frequently Asked Questions

How were Kinnate Biopharma's earnings last quarter?

Kinnate Biopharma Inc. (NASDAQ:KNTE) issued its earnings results on Thursday, May, 11th. The company reported ($0.73) EPS for the quarter, hitting analysts' consensus estimates of ($0.73).

When did Kinnate Biopharma IPO?

Kinnate Biopharma (KNTE) raised $170 million in an initial public offering on Thursday, December 3rd 2020. The company issued 10,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, SVB Leerink, Piper Sandler and Wedbush PacGrow served as the underwriters for the IPO.

What other stocks do shareholders of Kinnate Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kinnate Biopharma investors own include NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Meta Platforms (META), Canopy Growth (CGC) and DraftKings (DKNG).

Company Calendar

• Last Earnings: 5/11/2023
• Today: 5/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:KNTE
• CIK: 1797768
• Web: www.kinnate.com
• Phone: 858-299-4699
• Fax: N/A
• Employees: 84
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($2.78)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$116.27 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -62.31%
• Return on Assets: -54.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.80
• Quick Ratio: 10.80

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.06 per share
• Price / Book: 0.52

Miscellaneous

• Outstanding Shares: 47,220,000
• Free Float: 27,532,000
• Market Cap: $125.13 million
• Optionable: Optionable
• Beta: 1.38